MenaQ7 (Vitamin K2 MK-7, Natto-Derived) — Hermetica Encyclopedia
Branded Ingredient · Other

MenaQ7 (Vitamin K2 MK-7, Natto-Derived)

Strong Evidencevitamin

Hermetica Superfood Encyclopedia

The Short Answer

MenaQ7 is a patented form of vitamin K2 as menaquinone-7 (MK-7) derived from natto fermentation. It activates osteocalcin and matrix Gla protein to direct calcium into bones while preventing arterial calcification.

PubMed Studies
1
Validated Benefits
Synergy Pairings
At a Glance
CategoryBranded Ingredient
GroupOther
Evidence LevelStrong
Primary KeywordMenaQ7 benefits
Synergy Pairings5
MenaQ7 (Vitamin K2 MK-7, Natto-Derived) — botanical
MenaQ7 (Vitamin K2 MK-7, Natto-Derived) — botanical close-up

Health Benefits

Supports bone health by enhancing calcium absorption, reducing the risk of fractures by 25%. This is crucial for maintaining strong, healthy bones. - Promotes cardiovascular health by preventing arterial calcification, which can reduce the risk of heart disease. This supports a healthy circulatory system. - Enhances joint health by reducing inflammation, which can alleviate symptoms of arthritis and improve mobility. - Supports dental health by promoting strong teeth and preventing decay, which is essential for maintaining oral health. - Improves energy levels by supporting mitochondrial function, leading to increased stamina and reduced fatigue. This is important for an active lifestyle. - Acts as a powerful antioxidant, protecting cells from oxidative stress and reducing the risk of chronic diseases. This promotes overall health and longevity. - Supports immune function by modulating immune response, helping the body to fend off infections more effectively.

Origin & History

MenaQ7 (Vitamin K2 MK-7, Natto-Derived) — origin
Natural habitat

MenaQ7 is a patented form of Vitamin K2, specifically MK-7, derived from natto, a traditional Japanese fermented soybean product.

Vitamin K2 has been consumed in the form of natto in Japan for centuries, valued for its health benefits, particularly for bones and cardiovascular health.Traditional Medicine

Scientific Research

Research, including clinical trials, supports MenaQ7's role in improving bone mineral density and reducing arterial stiffness.

Preparation & Dosage

MenaQ7 (Vitamin K2 MK-7, Natto-Derived) — preparation
Traditional preparation

Typical dosage ranges from 90 to 200 mcg per day. Consult a healthcare provider before use.

Nutritional Profile

MenaQ7 is a highly purified, patented form of Vitamin K2 as Menaquinone-7 (MK-7), derived from fermented natto (soybeans fermented with Bacillus subtilis natto). It is not a macronutrient source and contains negligible calories, fat, protein, or carbohydrates in functional doses. Key bioactive compound: Menaquinone-7 (MK-7) — a fat-soluble vitamin belonging to the K2 subclass, typically dosed at 45–180 mcg per serving in supplemental form, with MenaQ7 standardized to ≥99% all-trans MK-7, the biologically active isomeric form. MK-7 has a long side chain (7 isoprene units) that confers exceptional bioavailability and a plasma half-life of approximately 72 hours, significantly longer than Vitamin K1 (phylloquinone, ~1–2 hours) or shorter-chain MK-4 (~6–8 hours). Bioavailability is notably fat-dependent — absorption increases substantially when taken with dietary fat due to its fat-soluble nature, utilizing chylomicron-mediated lymphatic transport. MenaQ7 activates two key carboxylation-dependent proteins: osteocalcin (bone Gla protein, BGP), which binds calcium into the bone matrix, and Matrix Gla Protein (MGP), the most potent known inhibitor of vascular calcification. At 180 mcg/day, studies show near-complete carboxylation of osteocalcin and MGP within 3 months. No significant mineral, fiber, or additional vitamin content is present at functional doses.

How It Works

Mechanism of Action

MenaQ7 functions as a cofactor for gamma-glutamyl carboxylase, which carboxylates vitamin K-dependent proteins including osteocalcin and matrix Gla protein (MGP). Activated osteocalcin binds calcium in bone tissue, while carboxylated MGP prevents calcium deposition in arterial walls. This dual mechanism ensures calcium is utilized for bone mineralization rather than soft tissue calcification.

Clinical Evidence

A 3-year randomized controlled trial with 244 postmenopausal women showed 180 mcg daily MenaQ7 reduced bone loss and improved bone strength. The same study demonstrated significant reduction in arterial stiffness markers. Additional studies indicate MenaQ7 can reduce fracture risk by up to 25% and improve cardiovascular markers, though most trials are conducted in postmenopausal women with limited data in other populations.

Safety & Interactions

MenaQ7 is generally well-tolerated with minimal side effects at recommended doses of 45-180 mcg daily. It may enhance the effects of warfarin and other anticoagulant medications, requiring medical supervision and potential dose adjustments. Unlike vitamin K1, MK-7 has a longer half-life and may have more pronounced interactions with blood thinners. Pregnant and breastfeeding women should consult healthcare providers before use due to limited safety data.

Synergy Stack

Hermetica Formulation Heuristic

Also Known As

Menaquinone-7MK-7Vitamin K2 MK-7Natto-derived menaquinone2-methyl-3-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]naphthalene-1,4-dioneNattokinase K2Fermented soy vitamin K2

Frequently Asked Questions

How much MenaQ7 should I take daily?
Clinical studies typically use 45-180 mcg of MenaQ7 daily, with 180 mcg showing optimal results for bone and cardiovascular health. Most supplements contain 100-120 mcg per serving, which aligns with effective dosing ranges.
Can I take MenaQ7 with calcium and vitamin D?
Yes, MenaQ7 works synergistically with calcium and vitamin D3 for optimal bone health. Vitamin D increases calcium absorption while MenaQ7 ensures calcium is directed to bones rather than soft tissues. This combination is often found in bone health formulations.
How long does it take for MenaQ7 to work?
MenaQ7 reaches steady-state levels in about 6 weeks with daily supplementation. Improvements in bone markers may be seen within 3-6 months, while cardiovascular benefits typically require 6-12 months of consistent use based on clinical studies.
Is MenaQ7 safe if I take blood thinners?
MenaQ7 may interact with warfarin and other anticoagulants, potentially affecting INR levels. Patients taking blood thinners should consult their physician before using MenaQ7 and may require more frequent monitoring of clotting times.
What makes MenaQ7 different from other vitamin K2 supplements?
MenaQ7 is a clinically studied, patented form of MK-7 with proven bioavailability and stability. It has a 72-hour half-life compared to MK-4's 1-hour half-life, allowing for once-daily dosing and sustained vitamin K activity throughout the body.
What foods contain MenaQ7 or natto-derived vitamin K2?
MenaQ7 is derived from natto, a fermented soybean product that is the richest natural food source of vitamin K2 MK-7. While natto is the primary dietary source, most people cannot consume enough natto regularly to meet therapeutic levels of K2, which is why MenaQ7 supplementation is often recommended. Other fermented foods like certain cheeses and some fermented vegetables contain K2, but typically in much lower amounts than natto.
Is MenaQ7 safe for children and the elderly?
MenaQ7 is generally recognized as safe for both children and elderly populations, though dosing should be adjusted based on age and individual health status. Elderly individuals particularly benefit from MenaQ7 for bone density support and cardiovascular health, as these concerns increase with age. Parents and caregivers should consult a healthcare provider to determine appropriate dosages for children, especially if other medications are involved.
What does clinical research show about MenaQ7's effectiveness for bone health?
Clinical studies demonstrate that MenaQ7 significantly enhances bone mineralization and can reduce fracture risk by approximately 25% through improved calcium utilization. Research shows MenaQ7 activates osteocalcin, a bone protein essential for binding calcium to the bone matrix, making it a key mechanism for supporting skeletal strength. Multiple peer-reviewed trials support MenaQ7's efficacy specifically for postmenopausal women and aging populations at higher risk for osteoporosis.

Explore the Full Encyclopedia

7,400+ ingredients researched, verified, and formulated for optimal synergy.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.